{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:03:39Z","timestamp":1757311419901},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,11,6]],"date-time":"2011-11-06T00:00:00Z","timestamp":1320537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11102-011-0361-9","type":"journal-article","created":{"date-parts":[[2011,11,5]],"date-time":"2011-11-05T01:43:14Z","timestamp":1320457394000},"page":"518-525","source":"Crossref","is-referenced-by-count":15,"title":["Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide"],"prefix":"10.1007","volume":"15","author":[{"given":"Elisabeth","family":"Couture","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanina","family":"Bongard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Maiza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,6]]},"reference":[{"key":"361_CR1","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189\u20133202","journal-title":"J Clin Invest"},{"key":"361_CR2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya CR, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667\u2013674","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR3","first-page":"32","volume":"36","author":"N Moller","year":"1991","unstructured":"Moller N, Jorgensen JO, Abildgard N, Orskov L, Schmitz O, Christiansen JS (1991) Effects of growth hormone on glucose metabolism. Horm Res 36:32\u201335","journal-title":"Horm Res"},{"key":"361_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ghir.2004.12.003","volume":"15","author":"N Mauras","year":"2005","unstructured":"Mauras N, Haymond MW (2005) Are the metabolic effects of GH and IGF-1 separable? Growth Horm IGF Res 15:19\u201327","journal-title":"Growth Horm IGF Res"},{"key":"361_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI20660","volume":"113","author":"DR Clemmons","year":"2004","unstructured":"Clemmons DR (2004) The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25\u201327","journal-title":"J Clin Invest"},{"key":"361_CR6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmonds D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509\u20131517","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mce.2008.02.007","volume":"286","author":"MZ Strowski","year":"2008","unstructured":"Strowski MZ, Blake AD (2008) Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol 286:169\u2013179","journal-title":"Mol Cell Endocrinol"},{"key":"361_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jc.87.1.99","volume":"87","author":"P Caron","year":"2002","unstructured":"Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico A, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99\u2013104","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR9","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva F, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141\u20133148","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 1","key":"361_CR10","first-page":"1","volume":"13","author":"AACE Diabetes Mellitus Clinical Practice Guidelines Task Force","year":"2010","unstructured":"AACE Diabetes Mellitus Clinical Practice Guidelines Task Force (2010) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl. 1):1\u201368","journal-title":"Endocr Pract"},{"issue":"8 supp","key":"361_CR11","first-page":"18","volume":"26","author":"G Angeletti","year":"2003","unstructured":"Angeletti G (2003) The metabolic complications of acromegaly. J Endocrinol Invest 26(8 supp):18\u201319","journal-title":"J Endocrinol Invest"},{"key":"361_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-07-0383","volume":"157","author":"A Colao","year":"2007","unstructured":"Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect on dose escalation of octreotide LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579\u2013587","journal-title":"Eur J Endocrinol"},{"key":"361_CR13","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1210\/jc.2003-030266","volume":"88","author":"R Atttanasio","year":"2003","unstructured":"Atttanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R (2003) Lanreotide 60\u00a0mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258\u20135265","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR14","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2008-2627","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso L, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analogue treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94:2907\u20132914","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/jc.2008-1546","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso L, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94:528\u2013537","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson Chazot F, Brue T, Delemer B (2011) Diabetes in acromegaly, prevalence, risk factors and evolution; data from the French acromegaly register. Eur J Endocrinol 164:877\u2013884","journal-title":"Eur J Endocrinol"},{"key":"361_CR17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2337\/diacare.26.1.61","volume":"26","author":"DECODE Study Group","year":"2003","unstructured":"DECODE Study Group (2003) Age-and-sex\u2013specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26:61\u201369","journal-title":"Diabetes Care"},{"key":"361_CR18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diabet.2008.01.005","volume":"34","author":"O Kusnik-Joinville","year":"2008","unstructured":"Kusnik-Joinville O, Weill A, Salanave B, Ricordeau P, Allemand H (2008) Prevalence and treatment of diabetes in France. Diabetes Metab 34:266\u2013272","journal-title":"Diabetes Metab"},{"key":"361_CR19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s12630-010-9391-4","volume":"57","author":"B Abdelmalak","year":"2010","unstructured":"Abdelmalak B, Abdelmalak JB, Knittel J, Christiansen E, Mascha E, Zimmerman R, Argalius M, Foss J (2010) The prevalence of undiagnosed diabetes in non cardiac surgery patients, an observational study. Can J Anesth 57:1058\u20131064","journal-title":"Can J Anesth"},{"key":"361_CR20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","volume":"34","author":"A Kreze","year":"2001","unstructured":"Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429\u20131433","journal-title":"Braz J Med Biol Res"},{"key":"361_CR21","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.2337\/dc08-0368","volume":"31","author":"B Balkau","year":"2008","unstructured":"Balkau B, Lange C, Fezeu L, Tichet J, Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S, Ducimeti\u00e8re P, Eschwege E (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 31:2056\u20132061","journal-title":"Diabetes Care"},{"key":"361_CR22","first-page":"20","volume":"60","author":"M Stelmachowska-Banas","year":"2009","unstructured":"Stelmachowska-Banas M, Zdunowski P, Zgliczynski W (2009) Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol Pol 60:20\u201324","journal-title":"Endokrynol Pol"},{"key":"361_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1563-2571.2000.00106.x","volume":"27","author":"H Biering","year":"2000","unstructured":"Biering H, Knappe G, Gerl H, Lochs H (2000) Prevalence of diabetes in acromegaly and cushing syndrome. Acta Med Austriaca 27:27\u201331","journal-title":"Acta Med Austriaca"},{"key":"361_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","volume":"26","author":"JD Nabarro","year":"1987","unstructured":"Nabarro JD (1987) Acromegay. Clin Endocrinol 26:481\u2013512","journal-title":"Clin Endocrinol"},{"key":"361_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1464-5491.2003.00827.x","volume":"20","author":"R Holt","year":"2003","unstructured":"Holt R, Simpson H, S\u00f6nksen P (2003) The role of the growth hormone\u2014insulin\u2014like factor axis in glucose homeostasis. Diabet Med 20:3\u201315","journal-title":"Diabet Med"},{"key":"361_CR26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J Clin Endocrinol Metab 94:1500\u20131508","journal-title":"J Clin Endocrinol Metab"},{"key":"361_CR27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","volume":"164","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannav\u00f2 S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164:341\u2013347","journal-title":"Eur J Endocrinol"},{"key":"361_CR28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","volume":"59","author":"R Baldelli","year":"2003","unstructured":"Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D\u2019Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogue treatment. Clin Endocrinol 59:492\u2013499","journal-title":"Clin Endocrinol"},{"key":"361_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/BF03345491","volume":"25","author":"C Ronchi","year":"2002","unstructured":"Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M (2002) Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 25:502\u2013507","journal-title":"J Endocrinol Invest"},{"key":"361_CR30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1020710800842","volume":"4","author":"S Webb","year":"2001","unstructured":"Webb S, Ortega E, Rodriguez-Espinosa J, Mato ME, Corcoy R (2001) Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient. Pituitary 4:275\u2013278","journal-title":"Pituitary"},{"key":"361_CR31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2005-837520","volume":"113","author":"B Gutt","year":"2005","unstructured":"Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J (2005) Four-year follow-up of acromegalic patients treated with the new long acting formulation of lanreotide (lanreotide Autogel). Exp Clin Endo Diabetes 113:139\u2013144","journal-title":"Exp Clin Endo Diabetes"},{"key":"361_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/eje.1.02185","volume":"155","author":"B Steffin","year":"2006","unstructured":"Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J (2006) Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73\u201378","journal-title":"Eur J Endocrinol"},{"key":"361_CR33","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1210\/jc.2001-011913","volume":"87","author":"J Ayuk","year":"2002","unstructured":"Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2002) Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 87:4142\u20134146","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-011-0361-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0361-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T02:08:13Z","timestamp":1559354893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-011-0361-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,6]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s11102-011-0361-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,6]]}}}